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81
As a core component of the RAF/MEK/ERK kinase cascade, MEK is a dual specific kinase that 82 transmits a signal from active RAF to phosphorylate ERK(8, 9) . The regulation of MEK is complex and
83 not yet completely understood. In RAF-driven cancers, active RAF mutants, such as BRAF(V600E),
84
activate MEK by phosphorylating its activation segment, which results in a high level of phospho-85 MEK(10). In contrast, the level of phospho-MEK is much lower in RTK/RAS-driven cancers, although 86 they have similar levels of MEK activity as indicated by comparable phospho-ERK level (11, 12) . This 87 suggests that wild-type active RAF activates MEK in a different way than BRAF(V600E). In addition, 88 some studies have indicated that AL-autophosphorylation of MEK might also contribute to its 89 activation(13-15), adding another layer of complexity to the regulation of MEK activity.
90
The activity of MEK is regulated not only by the AL-phosphorylation/dephosphorylation but also by 91 its interactions with other components of RAF/MEK/ERK kinase cascade (16) (17) (18) 
113

Results
114
The MEK mutation spectrum in cancer genomes.
115
To survey and characterize cancer-related MEK mutants, here we interrogated the ICGC
116
(International Cancer Genome Consortium) database, the cBioportal for Cancer Genomics database, 
132
To characterize MEK1 mutants with in-frame deletions of β3-αC loop, we measured their 133 activity in vivo and in vitro. As shown in Figure 1D -E and supplementary Figure 1B 
141
We next determined whether MEK inhibitors applied in therapy or in clinic trials(24) could be used 142 to target oncogenic MEK1 mutants with variable deletions of β3-αC loop. By using 293T transfectants 143 and stable fibroblast lines expressing these MEK1 mutants, we found that, among all inhibitors that 144 tested in this study, Tramentinib was the most effective in blocking the activity of MEK1(EI), while 145 MEK1(IHLEIK) was resistant to all inhibitors (Fig 2A and S2A 
152
In-frame deletions of β3-αC loop activate MEK1 through enhancing homodimerization.
153
In-frame deletions of β3-αC loop define a new group of oncogenic MEK1 mutations. However, (Fig 3B and S3B) , which further supports our hypothesis.
166
The activity of MEK1 is triggered by the enhanced homodimerization, suggesting that it has both 167 allosteric and catalytic functions as RAF kinases do. To examine the allosteric activity of MEK1 by 168 protein kinase co-activation assay(27-33), we created kinase-dead allosteric activators by deleting the 169 negative regulatory helix A (E44-E51) and fusing the catalytic spine (V82F mutation) in MEK1 170 mutants with variable deletions of β3-αC loop (Fig S3C) . MEK1(EI/helix A -/V82F) was the only 171 mutant capable of activating wild-type MEK1 when coexpressed in 293T cells, and its allosteric 172 activity was blocked by the GGAA mutation in dimer interface (Fig S3D-E) . The subtle allosteric 173 activity of MEK1(HLEI/ helix A -/V82F) and MEK1(IHLEIK/ helix A -/V82F) might arise from their 174 weak ability to dimerize with receiver ( Figure S3F ). Further, we examined whether a compound 175 MEK1 mutant mimicking active MEK1 with AL-phosphorylation has allosteric activity. As shown in 176 Figure 3C , the MEK1 mutant containing the helix A -, the V82F, and the DD (S218D, S221D), could 177 stimulate the activity of wild-type MEK1 as well as MEK1(EI/ helix A -/V82F) when co-expressed in 5 293T cells. Together, these data demonstrate that wild-type MEK1 has an ability of allosteric activator 179 once activated.
180
The AL-phosphorylation is an indicator of MEK fully activation(8). To explore the molecular basis 181 of MEK1 activation by enhanced homodimerization, we checked the AL-phosphorylation status of 182 MEK1 mutants with variable deletions of β3-αC loop, and found that the AL was phosphorylated in 183 MEK1(EI) and MEK1(HLEI) but not in MEK1(IHLEIK). Moreover, their AL-phosphorylation was 184 blocked by either catalytic spine fusion or dimer interface disruption (Fig 3D and S3G) . This data 185 suggested that MEK1 was turned on by homodimerization and then auto-phosphorylated its AL, and 186 that MEK1(IHLEIK) might mimic an intermediate locked in a transitional status. To further determine 187 whether the AL-autophosphorylation occurs in cis or trans, we purified the receiver from MEK1 co-188 activation transfectants and found that its AL was barely phosphorylated (Fig 3E) , suggesting that the 189 homodimerization drives a intradimer cross-phosphorylation of two protomers. This finding was also 190 supported by that the non-phosphorylatable AL-mutation (S217A/S221A) reduces the activity of 191 MEK1(EI) and MEK1(HLEI) by 60~70% but not that of MEK1(IHLEIK) (Fig 3F) . Overall, our data 192 demonstrated that in-frame deletions of β3-αC loop activate MEK1 via homodimerization-driven cross-193 phosphorylation (Fig 3G) .
195
MEK1 transduces a signal from active RAF to activate ERK in a dimer-dependent manner.
196
The interactions among different components play a crucial role in the signal transmission of 
211
BRAF(V600E) compared to wild-type MEK1 (Fig 4B) , indicating that the impaired AL- 
6
We next investigated whether active MEK functions as a dimer and requires dimeric ERK as 218 substrate for phosphorylation as active RAF does. Indeed, the disruption of dimer interface by 219 GGAA mutation impairs the activity of MEK1(DD) toward ERK which can be restored by GST fusion 220 (Fig 4C) , suggesting that active MEK really acts as a dimer. In contrast, wild-type and monomeric
221
ERK were phosphorylated equally when co-expressed with BRAF(V600E) or MEK1(DD) in 293T cells 222 (Fig 4D) , indicating that the dimerization of ERK is dispensable for its activation by MEK.
224
Discussion
226
In this study, we systematically characterized cancer-related MEK mutations, and found that MEK 
240
The activation of the RAF/MEK/ERK kinase cascade is a complex process involving physical 241 interactions among its components (16) (17) (18) . This process is initiated by RAF dimerization, which not 242 only turns on RAF but also facilitates the activation of MEK. Then MEK could be activated by RAF-243 mediated AL-phosphorylation, but also by homodimerization-driven AL-auto-phosphorylation. Like
244
RAF kinases, the dimerization of MEK is required for both its activation and catalytic function.
245
Together with previous findings, we propose the following model for the activation of the 246 RAF/MEK/ERK kinase cascade (Fig 4E) : (1) 
262
Materials and Methods
263
Antibodies, Biochemicals, Cell lines, and Plasmids
264
Antibodies used in this study include: anti-phosphoERK1/2, anti-phosphoMEK1/2, and anti- 
267
Trametinib, GDC0623, Cobimetinib, AZD6244, and Binimentinib were purchased from
268
Medchemexpress. All other chemicals were obtained from Sigma. Wild-type, BRAF -/-and CRAF -/-269 fibroblasts were generated in previous study(36). MeWo melanoma cell line was obtained from ATCC.
270
Plasmids encoding RAS, RAF, MEK, ERK, and their mutants were constructed by Gibson assembly. 
274
Protein expression and Purification 275 6xhis-tagged ERK2(K52A) was expressed in BL21(DE3) strains and purified by using Nickel 276 column (Qiagen) as described before(37). FLAG-tagged MEK1, MEK1(EI), MEK1(IHLEIK) were 277 expressed in 293T cells and purified by using anti-FLAG affinity gel and 3XFLAG peptide (Sigma) and 278 following manufacturer's protocol.
280
Cell Culture, Transfection, and Transduction
281
All cell lines were maintained in DMEM medium with 10% FBS (Hyclone). Cell transfection were 282 carried out by using the Biotool transfection reagent. To generate stable cell lines that express MEK1 283 mutants, viruses were prepared and applied to infect target cells according to our previous studies (37, 284 38) . Infected cells were selected by using antibiotics.
286
Immunoprecipitation, In Vitro Kinase Assay, and Western Blotting
287
Immunoprecipitations were performed as described previously (27) (28) (29) . Briefly, whole-cell lysates
288
were mixed with either anti-HA,or anti-FLAG beads (Sigma), rotated in cold room for 60 min, and 289 washed three times with RIPA buffer. For in vitro kinase assays, the immunoprecipitants were washed 290 once with kinase reaction buffer (25 mM HEPES, 10 mM MgCl2, 0.5 mM Na3VO4, 0.5 mM DTT, pH 291 7.4), then incubated with 20μl kinase reaction mixture (2 ug substrate and 100 mM ATP in 20μl kinase 292 reaction buffer) per sample at room temperature for 10 min. Kinase reaction was stopped by adding 293 5μl per sample 5XLaemmli sample buffer. Immunoblotting was carried out as described before(37).
295
Foci formation assay 
487
(C) Kinase-dead MEK1 is able to function as allosteric activator to stimulate wild-type MEK1. C-spine
